Published in Cancer Weekly, July 14th, 1997
"Both allogeneic and autologous dendritic-cell infusions were well-tolerated and, in patients with CD4+ T-cell counts >400 [cells/(mu)L], administration of these antigen-pulsed cells enhanced the immune response to HIV without affecting viral load," concluded Edgar G. Engleman of Stanford University, Palo Alto, California.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.